Cutia Therapeutics (HK:2487) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cutia Therapeutics’ CEO and Executive Director, Ms. Zhang Lele, has increased her shareholding in the company, purchasing a total of 28,000 shares in October 2024. This move signals her strong confidence in the company’s future prospects and business outlook. Investors are advised to remain cautious when trading Cutia Therapeutics’ shares.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.